MOKAN Wealth Management Inc. Raises Stake in Johnson & Johnson $JNJ

MOKAN Wealth Management Inc. increased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 19.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 14,115 shares of the company's stock after buying an additional 2,250 shares during the quarter. Johnson & Johnson accounts for approximately 1.2% of MOKAN Wealth Management Inc.'s portfolio, making the stock its 24th largest holding. MOKAN Wealth Management Inc.'s holdings in Johnson & Johnson were worth $2,156,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GFG Capital LLC purchased a new stake in Johnson & Johnson during the second quarter valued at about $35,000. Highline Wealth Partners LLC lifted its holdings in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson during the first quarter valued at about $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at about $48,000. Finally, von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Down 0.0%

JNJ stock opened at $190.88 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company's 50 day moving average is $179.28 and its 200 day moving average is $164.16. The stock has a market cap of $459.70 billion, a price-to-earnings ratio of 20.41, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $24.02 billion for the quarter. Sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Analysts Set New Price Targets

JNJ has been the topic of a number of analyst reports. Guggenheim raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their target price for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Citigroup upped their target price on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a "buy" rating in a report on Tuesday, October 7th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $176.00 to $178.00 and gave the stock an "equal weight" rating in a report on Friday, October 10th. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Finally, Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $193.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.